AKYNZEO® has a demonstrated safety profile in CINV patients

Safety was evaluated in >1000 patients receiving AKYNZEO capsules over 4500 cycles1

Adverse reactions occurring in ≥3% of patients receiving AKYNZEO and cisplatin-based chemotherapy regimens1

Adverse Reactions AKYNZEO capsules
(n=136)
Oral Palonosetron
0.5 mg (n=136)
Dyspepsia 4% 2%
Fatigue 4% 2%
Constipation 3% 1%
Erythema 3% 2%

A single-cycle study of patients receiving cisplatin-based, highly emetogenic chemotherapy (AKYNZEO, n=136).1


The safety profile of AKYNZEO for injection was generally similar to AKYNZEO capsules1

  • There were no infusion-site reactions related to AKYNZEO for injection2
  • AKYNZEO for injection contains NO polysorbate-80, a solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions1,3

See IV data


Adverse reactions occurring in ≥3% of cancer patients receiving AKYNZEO and AC-based chemotherapy regimens†,1

Adverse Reactions AKYNZEO capsules
(n=725)
Oral Palonosetron
0.5 mg (n=725)
Headache 9% 7%
Asthenia 8% 7%
Fatigue 7% 5%

A study of patients receiving AC-based chemotherapy treatment. 725 patients were treated with AKYNZEO capsules during Cycle 1; 635 of these patients continued for up to 8 cycles in a multiple-cycle extension.

 
AKYNZEO for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.
AC
=anthracycline-cyclophosphamide.
CINV
=chemotherapy-induced nausea and vomiting.